218 related articles for article (PubMed ID: 29779164)
1. Update on Endothelin Receptor Antagonists in Hypertension.
Burnier M
Curr Hypertens Rep; 2018 May; 20(6):51. PubMed ID: 29779164
[TBL] [Abstract][Full Text] [Related]
2. Endothelin Receptor Antagonists: New Hope for Renal Protection?
Tobe S; Kohan DE; Singarayer R
Curr Hypertens Rep; 2015 Jul; 17(7):57. PubMed ID: 26068660
[TBL] [Abstract][Full Text] [Related]
3. Endothelin A receptor antagonists in diabetic kidney disease.
Georgianos PI; Agarwal R
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):338-344. PubMed ID: 28520568
[TBL] [Abstract][Full Text] [Related]
4. Atrasentan for the treatment of diabetic nephropathy.
Egido J; Rojas-Rivera J; Mas S; Ruiz-Ortega M; Sanz AB; Gonzalez Parra E; Gomez-Guerrero C
Expert Opin Investig Drugs; 2017 Jun; 26(6):741-750. PubMed ID: 28468519
[TBL] [Abstract][Full Text] [Related]
5. Addition of ET(A) receptor blockade increases renoprotection provided by renin-angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats.
Čertíková Chábová V; Vernerová Z; Kujal P; Husková Z; Škaroupková P; Tesař V; Kramer HJ; Kompanowska-Jezierska E; Walkowska A; Sadowski J; Červenka L; Vaněčková I
Life Sci; 2014 Nov; 118(2):297-305. PubMed ID: 24373834
[TBL] [Abstract][Full Text] [Related]
6. Endothelin antagonism and hypertension: an evolving target.
Laffin LJ; Bakris GL
Semin Nephrol; 2015 Mar; 35(2):168-75. PubMed ID: 25966348
[TBL] [Abstract][Full Text] [Related]
7. Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease.
Smeijer JD; Kohan DE; Webb DJ; Dhaun N; Heerspink HJL
Curr Opin Nephrol Hypertens; 2021 Jul; 30(4):456-465. PubMed ID: 33990507
[TBL] [Abstract][Full Text] [Related]
8. Endothelin Receptor Antagonists in Kidney Disease.
Martínez-Díaz I; Martos N; Llorens-Cebrià C; Álvarez FJ; Bedard PW; Vergara A; Jacobs-Cachá C; Soler MJ
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834836
[TBL] [Abstract][Full Text] [Related]
9. Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension.
Heidari Nejad S; Azzam O; Schlaich MP
Curr Hypertens Rep; 2023 Oct; 25(10):343-352. PubMed ID: 37566184
[TBL] [Abstract][Full Text] [Related]
10. Endothelin antagonists in clinical trials: lessons learned.
Barton M; Kohan DE
Contrib Nephrol; 2011; 172():255-260. PubMed ID: 21894005
[TBL] [Abstract][Full Text] [Related]
11. Endothelin in diabetic renal disease.
Benz K; Amann K
Contrib Nephrol; 2011; 172():139-148. PubMed ID: 21893995
[TBL] [Abstract][Full Text] [Related]
12. Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy.
Enevoldsen FC; Sahana J; Wehland M; Grimm D; Infanger M; Krüger M
J Clin Med; 2020 Mar; 9(3):. PubMed ID: 32197449
[TBL] [Abstract][Full Text] [Related]
13. Moderate additive effects of endothelin receptor A blockade in Ren-2 transgenic rats subjected to various types of RAS blockade.
Vaněčková I; Řezáčová L; Kuneš J; Zicha J
Life Sci; 2016 Aug; 159():127-134. PubMed ID: 26775568
[TBL] [Abstract][Full Text] [Related]
14. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
[TBL] [Abstract][Full Text] [Related]
15. Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension.
Miyagawa K; Emoto N
Ther Adv Cardiovasc Dis; 2014 Oct; 8(5):202-16. PubMed ID: 24990369
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin system blockade alone or combined with ET
Sedláková L; Čertíková Chábová V; Doleželová Š; Škaroupková P; Kopkan L; Husková Z; Červenková L; Kikerlová S; Vaněčková I; Sadowski J; Kompanowska-Jezierska E; Kujal P; Kramer HJ; Červenka L
Clin Exp Hypertens; 2017; 39(2):183-195. PubMed ID: 28287881
[TBL] [Abstract][Full Text] [Related]
17. Endothelin and endothelin antagonists in chronic kidney disease.
Kohan DE; Barton M
Kidney Int; 2014 Nov; 86(5):896-904. PubMed ID: 24805108
[TBL] [Abstract][Full Text] [Related]
18. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
[TBL] [Abstract][Full Text] [Related]
19. Aprocitentan: A new development of resistant hypertension.
Yao Y; Fan B; Yang B; Jia Z; Li B
J Clin Hypertens (Greenwich); 2023 Jul; 25(7):587-590. PubMed ID: 37334561
[TBL] [Abstract][Full Text] [Related]
20. Endothelin receptor antagonism in portal hypertension.
Pitts KR
Expert Opin Investig Drugs; 2009 Feb; 18(2):135-42. PubMed ID: 19236261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
